Target intelligence / Profile preview

Gut microbiota and immune system

Molecular classification
Other, Community/ecosystem/metabolite axis, Involved receptors, enzymes, cell types (see below), but not classifiable as a single family
01

Overview

The "gut microbiota and immune system" describes the complex, dynamic interplay between the diverse microbial community inhabiting the gastrointestinal tract and the host's innate and adaptive immune systems. This axis regulates immune responses, maintains mucosal and barrier integrity, modulates inflammation, and impacts systemic metabolic and disease processes. Key mechanisms include direct microbial signaling to immune cells, production of metabolites (such as short-chain fatty acids) that modulate immune function, regulation of immunoglobulin (IgA, IgG) production, and maintenance of tolerance to commensals while defending against pathogens. Disruption of this balance ("dysbiosis") is implicated in a wide range of diseases, including inflammatory, autoimmune, metabolic, and malignant conditions.

Other names
Gut-immune axisMicrobiota-immunity axisMicrobiota–host immune interaction
02

Mechanism of action

Enhancement of beneficial bacteria to modulate immune responses; Suppression of pathogenic bacteria to reduce inflammation; Modulation of microbial metabolites (e.g., butyrate) that directly affect immune cells; Stimulation of barrier defenses (barrier effect).

03

Biological functions

Immune response: Training, induction, and regulation of innate and adaptive immunityInflammation: Production or suppression of inflammatory mediatorsBarrier defense: Maintenance of epithelial and mucosal barriersMetabolism: Synthesis of metabolites that influence immune cell function (e.g., short-chain fatty acids)
04

Disease associations

InflammationAutoimmune diseaseMetabolic disorders (type 2 diabetes, obesity)Cardiovascular diseaseCancerInfectious diseaseOther (neurological, allergic, gastrointestinal)
05

Safety considerations

Risk of infection if the microbiota balance is disturbed (dysbiosis)Immune overstimulation or suppression with microbiota-modifying therapiesTransfer of antimicrobial resistance genes with some interventions
06

Interacting drugs

Probiotics (e.g., Lactobacillus species, Bifidobacterium species)

4 more in the full profile.

07

Biomarkers

Fecal microbiota composition and diversityCirculating and mucosal immunoglobulin A levelsInflammatory cytokines (e.g., IL-18, IL-22)Short-chain fatty acid (SCFA) levels in stool

Beyond the preview

Go deeper on Gut microbiota and immune system.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbiota and immune system.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call